Comparative Pharmacology
Head-to-head clinical analysis: AMITRIL versus ASENDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITRIL versus ASENDIN.
AMITRIL vs ASENDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.
Amoxapine, a dibenzoxazepine tricyclic antidepressant, primarily inhibits the reuptake of norepinephrine and serotonin. Its metabolite, 7-hydroxyamoxapine, exhibits dopamine D2 receptor antagonism, contributing to its antipsychotic effects.
Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.
50 mg orally three times daily, increased gradually to 100-200 mg/day in divided doses. Max 300 mg/day.
None Documented
None Documented
Terminal elimination half-life: 15–25 hours (mean 20 h); may extend to >40 h in elderly or hepatic impairment.
Terminal elimination half-life is approximately 24-30 hours. Clinical context: Steady-state is reached within 5-7 days; the half-life supports once-daily dosing in most patients.
Renal: ~70% as metabolites, <5% unchanged; fecal: ~30% via bile.
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (30-40%), with the remainder as other metabolites; <10% excreted unchanged in urine.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant